AIM ImmunoTech's stock delisted from NYSE American due to low selling price, moving to Pink Market.

From GlobeNewswire: 2025-04-04 16:45:00

AIM ImmunoTech Inc. has been notified by NYSE Regulation of the NYSE American LLC that trading of the Company’s common stock has been suspended due to the low selling price. The Company plans to appeal this determination, but there is no guarantee of success. The stock is expected to begin trading on the Pink Open Market on April 7, 2025. AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19, with a lead product called Ampligen® (rintatolimod). For more information, visit aimimmuno.com.

The Company has filed a Form 8-K with the SEC on April 4, 2025, which contains additional details regarding the trading suspension and delisting proceedings. AIM ImmunoTech Inc. urges investors to consider the risk factors identified in its most recent Form 10-K and subsequent filings with the SEC. The forward-looking statements made by the Company only reflect information available as of the date of the announcement, and there is no obligation to update them unless required by law.



Read more at GlobeNewswire: AIM ImmunoTech Announces NYSE American Notice of Delisting